Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 40 clinical trials
CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer

To evaluate the feasibility of administering HCQ, EVE or the combination in patients who have completed primary therapy for breast cancer and harbor bone marrow disseminated tumor cells.

invasive breast cancer
tumor cells
triple-negative breast cancer
primary tumor
  • 14 Jun, 2022
  • 1 location
Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer (POLAR)

POLAR is a phase III clinical trial, which will test the safety and efficacy of an investigational combination of drugs to learn whether the combination of drugs works for a specific cancer. Palbociclib (Ibrance) is the name of the investigational agent, which is assessed together with standard anti-hormone therapy in …

estrogen receptor
hormone therapy
  • 19 Feb, 2022
  • 55 locations
Effect of PACK Health Support Program on Patient Reported Outcomes in Patients With Breast Cancer

This trial studies the effect of an electronic health (eHealth) support program called PACK Health on patient reported health outcomes in patients with breast cancer. PACK Health monitors breast cancer patients' reported side effects and experience of care when receiving chemotherapy. Participating in the PACK Health coaching program may improve …

invasive breast cancer
ductal carcinoma
carcinoma in situ
breast cancer
  • 12 Jul, 2022
  • 1 location
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer

This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it …

other malignancy
hormone therapy
ace inhibitor
heart failure
coronary artery disease
  • 26 Feb, 2022
  • 114 locations
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic …

other malignancy
palliative radiation therapy
chemotherapy regimen
solid tumour
bone marrow procedure
  • 08 Aug, 2022
  • 909 locations
Artificial Intelligence Supporting CAncer Patients Across Europe - the ASCAPE Project

ASCAPE (Artificial intelligence Supporting CAncer Patients across Europe) is a collaborative research project involving 15 partners from 7 countries, including academic medical centers, SMEs (small and medium-sized enterprises), research centers and universities, aiming to leverage the recent advances in Big Data and AI (Artificial Intelligence) to support cancer patients' Quality …

  • 23 May, 2021
  • 4 locations
KORTUC Phase II - Intra-tumoural Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer

radiotherapy in patients with locally advanced or recurrent breast cancer. Laboratory research and initial clinical trials in Japan suggest that 4 to 6 injections of a radiation sensitiser ('KORTUC') based on

locally advanced breast cancer
advanced breast cancer
  • 13 Mar, 2022
  • 6 locations
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics (CHARGE)

This is an open-label, multi-center, phase I study designed to assess the maximum tolerated dose of ribociclib and belinostat in combination. The trial will open with a dose escalation followed by an expansion cohort at the identified dose. Dose escalation will be open to the enrollment of patients diagnosed with …

breast cancer
measurable disease
  • 11 May, 2022
  • 2 locations
Combination Study of SV-BR-1-GM in Combination With INCMGA00012 and Epacadostat

This is an open-label study of Study WRI-GEV-007, which evaluates SV-BR-1-GM in metastatic or locally recurrent breast cancer patients, in combination with the PD-1 inhibitor INCMGA00012 and the

stage iv breast cancer
advanced breast cancer
  • 30 May, 2022
  • 7 locations
B002 in Patients With HER2-positive Breast Cancer (B002-101)

To assess the safety and tolerability characteristics of B002 in patients with HER2-positive recurrent or metastatic breast cancer. The dose-limiting toxicity (DLT) was assessed and the maximum tolerated dose (MTD) was explored.

bone metastases
breast cancer
monoclonal antibody therapy
primary tumor
  • 10 Aug, 2022
  • 1 location